“I want to reiterate that this study doesn't necessarily say that 1 approach is better than the other, but it definitely does reinforce some advantages of robotic surgery that have been shown not just in this study, but in other studies as well,” says Peter Chang, MD, PhD.
In this video Peter Chang, MD, PhD, discusses the key takeaways from the Journal of Urology study, “Prospective multicenter comparison of open and robotic radical prostatectomy: The PROST-QA/RP2 consortium.” Specifically, he emphasizes how the efficacy of the prostatectomy relies on skill of surgeon and the individualized case itself. Chang is an assistant professor of surgery at Harvard Medical School and the director of the Prostate Cancer Care Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.